



# Unite to END TB: Leave no one behind

क्षयरोग अन्त्यका लागि सबै संगठित होऔं-सबैलाई संगसगै लौजाऔं

## Nepal Tuberculosis Profile

Population 2025	Billion	
Estimates of TB burden*, 2025	Number (Thousands)	Rate per 100,000 Population
Mortality (includes HIV-TB)	5.4 (3.9-7.6)	20 (14-30)
Mortality (HIV-TB Excl.)	0.5 (0.20-0.62)	1.7 (1.4-2)
Incidence (includes HIV-TB)	44 (38-50)	28 (25-37)
Incidence (HIV-TB excl.)	1.9 (1.5-2.4)	6.7 (5.2-8.4)
Incidence (MDR/RR-TB)**	1.5 (0.8-2.1)	5.8 (3.3-7.4)

Estimated TB incidence by age and sex (Thousand)*, 2025			
Sex	0-14 years	15-74 years	Total
Females	2.4 (1.4-3.4)	34 (3.5-35)	36 (3.5-35)
Males	2.9 (1.9-3.7)	25 (2.9-33)	28 (2.9-33)
Total	5.2 (4.3-6.4)	59 (6-40)	64 (6-40)

TB case notifications, 2024	
Total cases notified	52,096
Total new and relapse	51,214
% based with rapid diagnosis at time of diagnosis	28%
% with known HIV status	2%
% pulmonary	79%
% microbiologically confirmed among pulmonary	70%
% of childhood TB case diagnosed	1.54%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2025	79% (68-85)
TB patient financing (straight total cost)	
TB Case fatality ratio (estimated mortality/estimated incidence), 2025	1.24 (0.9-1.6)

TB, HIV cases in new and relapse TB patients, 2024		
	Number	%
Patients with known HIV status who are HIV-positive on antiretroviral therapy	155	9%
	227	28%

Drug-resistant TB cases, 2025			
	New Cases	Previously Treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			90 (80-1,300)

Estimated % of TB cases with MDR/RR-TB	2.2% (0.4-1.4)	5% (3.3-7.2)	
% notified isoniazid rifampicin resistance	12%	2%	451
MDR/RR-TB cases started on resistance to second-line drugs			32
Laboratory-confirmed cases		MDR/RR-TB (XDR, TDR)	
Patients started on treatment****		MDR/RR-TB (XDR, TDR)	


Treatment success rate and retention			
	Success	Other	
New and relapse cases registered in 2025	93%		31,707
Previously treated cases, including relapse, registered in 2025	92%		1,267
HIV Positive TB cases, all types, regular in 2025	8%		18
MDR/RR-TB cases started on second-line treatment in 2024	7%		28
XDR-TB cases started on second-line treatment in 2024			

\* Ranges represent uncertainty intervals  
 \*\* MDR is TB resistant to rifampicin and isoniazid, RR is TB resistant to rifampicin  
 \*\*\* Includes cases with unknown previous TB treatment history  
 \*\*\*\* Includes patients diagnosed before 2022 and patients who were not laboratory-confirmed


## Key facts regarding Facilities

Treatment Facilities		Laboratory Facilities	
Facilities	No.	Facilities	No.
DOT Centers	4321	Microscopy Centers	581
Urban DOT	96	Gene-Rpert facility	27
MDR Treatment Centers	24	Culture labs and DST	2
MDR Treatment Sub Centers	81	Line Probe Assay (LPA)	2
DR Hostel	6		
DR Home	1		


## Case Notification



## Age Distribution of New and Relapse TB Cases



## Treatment Success



## DR TB Cases



## Treatment Success Rate of DR TB

